Eli Lilly plans to slash the cost of some of its most popular insulin drugs later this year for people with and without insurance, in a move that could make the lifesaving medication more affordable for some patients living with diabetes.
The company is capping the out-of-pocket cost of its insulin at $35 a month for people who have private insurance or Medicare and for people without insurance who are enrolled in its Insulin Value Program, CNN reports.
Lilly is also planning to cut the list prices for some of its most popular, albeit older, insulin products by 70% or more, starting in October.
